Quick Answer
MYRIAD GENETICS INC reported Diluted EPS of $3.95 per share (loss) for fiscal year 2025.
MYRIAD GENETICS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.95 | -180.1% |
| 2024 | -$1.41 | +55.7% |
| 2023 | -$3.18 | -128.8% |
| 2022 | -$1.39 | -297.1% |
| 2021 | -$0.35 | +88.3% |
| 2020 | -$2.99 | -11.2% |
| 2020 | -$2.69 | -4583.3% |
| 2019 | $0.06 | -96.8% |
| 2018 | $1.85 | +640.0% |
| 2017 | $0.25 | -84.4% |
| 2016 | $1.60 | +49.5% |
| 2015 | $1.07 | -52.4% |
| 2014 | $2.25 | +27.1% |
| 2013 | $1.77 | +36.2% |
| 2012 | $1.30 | +18.2% |
| 2011 | $1.10 | -28.6% |
| 2010 | $1.54 | +79.1% |
| 2009 | $0.86 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.29 | -20.8% | +91.9% |
| June 30, 2025 | -$3.57 | -770.7% | — |
| March 31, 2025 | $0.00 | +100.0% | +100.0% |
| September 30, 2024 | -$0.24 | +68.0% | +41.5% |
| June 30, 2024 | -$0.41 | +71.1% | -41.4% |
| March 31, 2024 | -$0.29 | +56.7% | +61.3% |
| September 30, 2023 | -$0.75 | -74.4% | +47.2% |
| June 30, 2023 | -$1.42 | -688.9% | -111.9% |
- MYRIAD GENETICS INC showed a decrease of -180.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2009–2025 period, MYRIAD GENETICS INC’s diluted eps has declined by 559.3% (from $0.86 per share to $3.95 per share (loss)).
- The most recent figure is from MYRIAD GENETICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: